David Edmondson, DO
Allergy · Wausau, WINPI 1124079033
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $182,825 of the $207,207 with a category attached, or 88.2%. AstraZeneca accounts for 87.6% of it on its own, with 14 other manufacturers making up the rest.
Across 219 payments — averaging $946.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$182K
- Amgen$21K
- Regeneron Healthcare Solutions, Inc.$3K
- Jubilant Hollisterstier LLC$1K
- Genentech USA, Inc.$67
- Acclarent, Inc$33
- plus $159 from 9 others
Across 3 payments — averaging $11,892 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$36K
What the payments were for
- Consulting fees$8,1894%
- Speaking & faculty fees$182,82588%
- Travel & lodging$11,1805%
- Food & beverage$4,9782%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 177 | $181,558 |
| Amgen | 21 | $21,178 |
| Regeneron Healthcare Solutions, Inc. | 5 | $3,211 |
| Jubilant Hollisterstier LLC | 1 | $1,000 |
| Genentech USA, Inc. | 4 | $67 |
| Acclarent, Inc | 1 | $33 |
| Shire North American Group Inc | 2 | $28 |
| CSL Behring | 1 | $20 |
| Aerin Medical Inc. | 1 | $19 |
| Octapharma USA, Inc. | 1 | $17 |
| Alk-abello, Inc | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Grifols USA, LLC | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy providers in Wisconsinto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 20 | $106,229 |
| Dupixent SyringeDupilumab | 27 | $101,582 |
| Breo ElliptaFluticasone/Vilanterol | 127 | $60,681 |
| Advair HfaFluticasone Propion/Salmeterol | 105 | $36,535 |
| XolairOmalizumab | 19 | $33,944 |
| DuleraMometasone/Formoterol | 45 | $22,379 |
| Spiriva RespimatTiotropium Bromide | 41 | $21,295 |
| Arnuity ElliptaFluticasone Furoate | 76 | $19,721 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 127 | $16,844 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $12,871 |
| Spiriva HandihalerTiotropium Bromide | 22 | $11,018 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 49 | $9,526 |
| Epinephrine | 42 | $8,922 |
| Fluticasone Propionate HfaFluticasone Propionate | 28 | $8,261 |
| Ipratropium Bromide | 164 | $5,666 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat | $13 | $21,29541 claims |
| AstraZenecaSymbicort | $181,558 | $12,87148 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Wisconsinon file to place this against a meaningful peer group, so we don't.
Other allergy in Wausau
- Gary StevenGreenfield$153K
- Mark MossMadison$16K
- Ravi ViswanathanMadison$4K
- Courtney GaberinoMadison$1K
- Helen SandersonMadison$762
- Pedro BandaMilwaukee$149
- Martin LobelMilwaukee$123
- Ivana SurjancevMadison$34
- Mark BiagtanMadison$19
- Michael GanzRacine$11
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.